Evaxion A/S

EVAX · NASDAQ

$3.76+$0.05 (+1.35%)TodayMarket closed · Oct 23, 7:43 PM ET

Prev close $3.71

EVAX analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $12.49 (+232.3% upside)

Low: $9.09
Now: $3.76
High: $16.80

Upgrades and downgrades

The latest rating actions, newest first

EVAX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Apr 24, 2026	Maintains	Buy	$16.00	43%
Jones Trading	Mar 10, 2026	Initiates	Buy	$10.00	—
Lake Street	Mar 9, 2026	Maintains	Buy	$11.00 → $9.00	26%
HC Wainwright & Co.	Mar 9, 2026	Maintains	Buy	$16.00	43%
Edward Jones	Oct 30, 2025	Initiates	Buy	$10.00	31%

The case for and against

Updated Aug 25, 2026

Bull case

Evaxion is developing novel vaccines using their proprietary AI platform, AI-Immunology, which decodes the human immune system to target cancer and infectious diseases. The company's strong focus on personalized treatment options, with 15 shared ERV antigens across 95% of AML patients in their Phase 1 trial, showcases their potential in the market. With sufficient funding into 2H27, the company plans to pivot into autoimmune disease therapies, with their AI-Immunology model set to select 2-3 lead indications in 1H26. This strategic move could positively impact their licensing strategy and further drive their growth in the future.

Bear case

Evaxion is a clinical-stage TechBio company that is facing several potential risks, including potential technology and clinical issues, as well as competition in the market. Despite presenting strong data, the company is still in the early stages of developing its pipeline, and there are currently no approved products. Its financials show a strong balance sheet, but with multiple clinical candidates in different disease areas, it may be difficult to fully capitalize on the potential value of each candidate. Overall, the company's outlook is dependent on its ability to successfully progress its pipeline and secure partnerships and collaborations to drive future revenue and growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.